LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40
Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals Reprices CEO Stock Options
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals Reports Independent Confirmation Of Positive Biopsy Results In All Patients Treated With ELX-02 In Phase 2 Clinical Study For Alport Syndrome
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
